Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers

Journal of Lipid Research

Volumn 50, Issue 4, 2009, Pages 730-739

  van Himbergen, Thomas M ^a,b   Matthan, Nirupa R ^a   Resteghini, Nancy A ^a,b   Otokozawa, Seiko ^a   Ai, Masumi ^a   Stein, Evan A ^c   Jones, Peter H ^d   Schaefer, Ernst J ^a,b  

^a TUFTS UNIVERSITY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Metabolic and Atherosclerosis Research Center   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Campesterol; Lathosterol; Plasma sterols; Sitosterol; STELLAR study

Indexed keywords

ATORVASTATIN; CAMPESTEROL; CHOLESTANOL; GLYCOSYLATED ALBUMIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LATHOSTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SITOSTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER; CHOLESTEROL; DRUG DERIVATIVE; FLUOROBENZENE; GLYCOSYLATED SERUM ALBUMIN; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; PHYTOSTEROL; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SERUM ALBUMIN; STEROL; SULFONAMIDE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; FEMALE; GAS LIQUID CHROMATOGRAPHY; GLYCEMIC CONTROL; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ABSORPTION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX RATIO; TRIACYLGLYCEROL BLOOD LEVEL; ABSORPTION; AGED; BIOSYNTHESIS; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; HYPERLIPIDEMIA; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ABSORPTION; ADULT; AGED; BIOLOGICAL MARKERS; CHOLESTEROL; DIABETES COMPLICATIONS; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; PHYTOSTEROLS; PYRIMIDINES; PYRROLES; SERUM ALBUMIN; STEROLS; SULFONAMIDES;

EID: 67449123465     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P800042-JLR200     Document Type: Article

References (39)

1. Baigent, C., A. Keech, P. M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, et al. 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 366: 1267-1278.
2. Schachter, M. 2005. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin. Pharmacol. 19: 117-125.
3. Pedro-Botet, J., E. J. Schaefer, R. G. Bakker-Arkema, D. M. Black, E. M. Stein, D. Corella, and J. M. Ordovas. 2001. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis. 158: 183-193.
4. Thompson, G. R., F. O'Neill, and M. Seed. 2002. Why some patients respond poorly to statins and how this might be remedied. Eur. Heart J. 23: 200-206.
5. Matthan, N. R., and A. H. Lichtenstein. 2004. Approaches to measuring cholesterol absorption in humans. Atherosclerosis. 174: 197-205.
6. Miettinen, T. A., R. S. Tilvis, and Y. A. Kesaniemi. 1990. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am. J. Epidemiol. 131: 20-31.
7. Miettinen, T. A., and H. Gylling. 2003. Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment. Eur. J. Clin. Invest. 33: 976-982.
8. Vanhanen, H., Y. A. Kesaniemi, and T. A. Miettinen. 1992. Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, fecal steroids, and cholesterol absorption in man. Metabolism. 41: 588-595.
9. Vanhanen, H. T., and T. A. Miettinen. 1995. Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination. Atherosclerosis. 115: 135-146.
10. Duane, W. C. 1993. Effects of lovastatin and dietary cholesterol on sterol homeostasis in healthy human subjects. J. Clin. Invest. 92: 911-918.
11. Miettinen, T. A., T. E. Strandberg, and H. Gylling. 2000. Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol. Arterioscler. Thromb. Vasc. Biol. 20: 1340-1346.
12. Jones, P. H., D. B. Hunninghake, K. C. Ferdinand, E. A. Stein, A. Gold, R. J. Caplan, and J. W. Blasetto. 2004. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin. Ther. 26: 1388-1399.
13. Jones, P. H., M. H. Davidson, E. A. Stein, H. E. Bays, J. M. McKenney, E. Miller, V. A. Cain, and J. W. Blasetto. 2003. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol. 92: 152-160.
14. Ai, M., S. Otokozawa, B. F. Asztalos, K. Nakajima, E. Stein, P. H. Jones, and E. J. Schaefer. 2008. Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels. Am. J. Cardiol. 101: 315-318.
15. Kouzuma, T., Y. Uemastu, T. Usami, and S. Imamura. 2004. Study of glycated amino acid elimination reaction for an improved enzymatic glycated albumin measurement method. Clin. Chim. Acta. 346: 135-143.
16. Matthan, N. R., A. Giovanni, E. J. Schaefer, B. G. Brown, and A. H. Lichtenstein. 2003. Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL. J. Lipid Res. 44: 800-806.
17. Chan, Y. M., K. A. Varady, Y. Lin, E. Trautwein, R. P. Mensink, J. Plat, and P. J. Jones. 2006. Plasma concentrations of plant sterols: physiology and relationship with coronary heart disease. Nutr. Rev. 64: 385-402.
18. Kronmal, R. A. 1993. Spurious correlation and the fallacy of the ratio standard revisited. J. R. Stat. Soc. Ser. A Stat. Soc. 156: 379-392.
19. Assmann, G., P. Cullen, J. Erbey, D. R. Ramey, F. Kannenberg, and H. Schulte. 2006. Plasma sitosterol elevations are associated with an increased incidence of coronary events in men: results of a nested case-control analysis of the Prospective Cardiovascular Munster (PROCAM) study. Nutr. Metab. Cardiovasc. Dis. 16: 13-21.
20. Lamon-Fava, S., M. R. Diffenderfer, P. H. Barrett, A. Buchsbaum, N. R. Matthan, A. H. Lichtenstein, G. G. Dolnikowski, K. Horvath, B. F. Asztalos, V. Zago, et al. 2007. Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism. J. Lipid Res. 48: 1746-1753.
21. Miettinen, T. A., H. Gylling, N. Lindbohm, T. E. Miettinen, R. A. Rajaratnam, and H. Relas. 2003. Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. J. Lab. Clin. Med. 141: 131-137.
22. Smahelova, A., R. Hyspler, T. Haas, A. Ticha, V. Blaha, and Z. Zadak. 2005. Effect of atorvastatin on non-cholesterol sterols in patients with type 2 diabetes mellitus and cardiovascular disease. Pharmacol. Res. 51: 31-36.
23. Watts, G. F., D. C. Chan, P. H. Barrett, F. H. O'Neill, and G. R. Thompson. 2003. Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome. Int. J. Obes. Relat. Metab. Disord. 27: 862-865.
24. Naoumova, R. P., A. D. Marais, J. Mountney, J. C. Firth, N. B. Rendell, G. W. Taylor, and G. R. Thompson. 1996. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia. Atherosclerosis. 119: 203-213.
25. Ooi, E. M., P. H. Barrett, D. C. Chan, P. J. Nestel, and G. F. Watts. 2008. Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome. Atherosclerosis. 197: 139-146.
26. Yu, L., J. Li-Hawkins, R. E. Hammer, K. E. Berge, J. D. Horton, J. C. Cohen, and H. H. Hobbs. 2002. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J. Clin. Invest. 110: 671-680.
27. Kajinami, K., M. E. Brousseau, C. Nartsupha, J. M. Ordovas, and E. J. Schaefer. 2004. ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin. J. Lipid Res. 45: 653-656.
28. Sudhop, T., D. Lutjohann, A. Kodal, M. Igel, D. L. Tribble, S. Shah, I. Perevozskaya, and K. von Bergmann. 2002. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 106: 1943-1948.
29. Jakulj, L., M. D. Trip, T. Sudhop, K. von Bergmann, J. J. Kastelein, and M. N. Vissers. 2005. Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe: effects on plasma lipid levels. J. Lipid Res. 46: 2692-2698.
30. Kastelein, J. J., F. Akdim, E. S. Stroes, A. H. Zwinderman, M. L. Bots, A. F. Stalenhoef, F. L. Visseren, E. J. Sijbrands, M. D. Trip, E. A. Stein, et al. 2008. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358: 1431-1443.
31. Ballantyne, C. M., R. Weiss, T. Moccetti, A. Vogt, B. Eber, F. Sosef, and E. Duffield. 2007. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am. J. Cardiol. 99: 673-680.
32. Glueck, C. J., J. Speirs, T. Tracy, P. Streicher, E. Illig, and J. Vandegrift. 1991. Relationships of serum plant sterols (phytosterols) and cholesterol in 595 hypercholesterolemic subjects, and familial aggregation of phytosterols, cholesterol, and premature coronary heart disease in hyperphytosterolemic probands and their first-degree relatives. Metabolism. 40: 842-848.
33. Sudhop, T., B. M. Gottwald, and K. von Bergmann. 2002. Serum plant sterols as a potential risk factor for coronary heart disease. Metabolism. 51: 1519-1521.
34. Rajaratnam, R. A., H. Gylling, and T. A. Miettinen. 2000. Independent association of serum squalene and noncholesterol sterols with coronary artery disease in postmenopausal women. J. Am. Coll. Cardiol. 35: 1185-1191.
35. Pinedo, S., M. N. Vissers, K. von Bergmann, K. Elharchaoui, D. Lutjohann, R. Luben, N. J. Wareham, J. J. Kastelein, K. T. Khaw, and S. M. Boekholdt. 2007. Plasma levels of plant sterols and the risk of coronary artery disease: the prospective EPIC-Norfolk Population Study. J. Lipid Res. 48: 139-144.
36. Miettinen, T. A., H. Gylling, T. Strandberg, and S. Sarna. 1998. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. BMJ. 316: 1127-1130.
37. Uusitupa, M. I., T. A. Miettinen, P. Happonen, T. Ebeling, H. Turtola, E. Voutilainen, and K. Pyorala. 1992. Lathosterol and other noncholesterol sterols during treatment of hypercholesterolemia with lovastatin alone and with cholestyramine or guar gum. Arterioscler. Thromb. 12: 807-813.
38. Miettinen, T. A., and H. Gylling. 2002. Ineffective decrease of serum cholesterol by simvastatin in a subgroup of hypercholesterolemic coronary patients. Atherosclerosis. 164: 147-152.
39. Assmann, G., F. Kannenberg, D. R. Ramey, T. A. Musliner, S. W. Gutkin, and E. P. Veltri. 2008. Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia. Curr. Med. Res. Opin. 24: 249-259.